Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients

Cytometry Part B - Clinical Cytometry

Volumn 86, Issue 1, 2014, Pages 32-43

  Monserrat, Jorge ^a   Sánchez, Miguel Ángel ^a   De Paz, Raquel ^d   Díaz, David ^a   Mur, Sonia ^a   Reyes, Eduardo ^a   Prieto, Alfredo ^a   De La Hera, Antonio ^a   Martínez A, Carlos ^b   Álvarez Mon, Melchor ^a,c  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

B CLL; CD4 T lymphocytes; flow cytometry; intracellular cytokine production; ZAP 70

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PROTEIN KINASE ZAP 70; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL INCLUSION; CELLULAR DISTRIBUTION; CENTRAL MEMORY CELL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; NON TERMINATED MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE SUBPOPULATION; TERMINATED MEMORY CELL; VERY ELDERLY;

B-CLL; CD4 T LYMPHOCYTES; FLOW CYTOMETRY; INTRACELLULAR CYTOKINE PRODUCTION; ZAP-70;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; B-LYMPHOCYTE SUBSETS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; UP-REGULATION; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84890548695     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21120     Document Type: Article

References (56)

1. Kipps TJ,. Chronic lymphocytic leukemia and related diseases. In:, Beutler E, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaunshanky K, Prchal JT, editors. Hematology. 7th ed. New York: McGraw-Hill Inc. 2006; 1343-1384.
2. Rozman C, Montserrat E,. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052-1057.
3. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS,. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
4. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
5. Montserrat E,. Classical and new prognostic factors in chronic lymphocytic leukemia: Where to now? Hematol J 2002; 3: 7-9.
6. Shanafelt TD, Geyer SM, Kay NE,. Prognosis at diagnosis: Integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 1202-1210.
7. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C,. Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic significance. Br J Haematol 1986; 62: 567-575.
8. Rozman C, Montserrat E, Rodriguez-Fernandez JM, Ayats R, Vallespi T, Parody R, Rios A, Prados D, Morey M, Gomis F, et al. Bone marrow histologic pattern-The best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases. Blood 1984; 64: 642-648.
9. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P,. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
10. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I, Thiel E, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999; 93: 1732-1737.
11. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, Binet JL, Merle-Beral H, Bron D,. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259-4264.
12. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
13. Bosch F, Muntanola A, Gine E, Carrio A, Villamor N, Moreno C, Crespo M, Montserrat E,. Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006; 70B: 214-217.
14. Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J, Moroy T, Klein-Hitpass L, Duhrsen U,. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17: 2426-2434.
15. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM, Oscier DG,. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105-111.
16. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951.
17. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat E,. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
18. Moreno C, Montserrat E,. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22: 211-219.
19. Chan AC, Iwashima M, Turck CW, Weiss A,. ZAP-70: A 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992; 71: 649-662.
20. Alvarez-Mon M, Casas J, Laguna R, Jorda J, Durantez A,. Clinical signification of natural killer activity in B-cell chronic lymphocytic leukemia. Eur J Haematol 1987; 38: 268-273.
21. Alvarez de MM, Casas J, Laguna R, Toribio ML, de Landazuri MO, Durantez A,. Lymphokine induction of NK-like cytotoxicity in T cells from B-CLL. Blood 1986; 67: 228-232.
22. Mellstedt H, Choudhury A,. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother 2006; 55: 210-220.
23. Scrivener S, Goddard RV, Kaminski ER, Prentice AG,. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003; 44: 383-389.
24. Reyes E, Prieto A, Carrion F, Garcia-Suarez J, Esquivel F, varez-Mon M,. Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities. Am J Hematol 1997; 55: 175-182.
25. Reyes E, Prieto A, Carrion F, Garcia-Suarez J, Esquivel F, Guillen C, Alvarez-Mon M. Altered pattern of cytokine production by peripheral blood CD2+ cells from B chronic lymphocytic leukemia patients. Am J Hematol 1998; 57: 93-100.
26. Christopoulos P, Pfeifer D, Bartholome K, Follo M, Timmer J, Fisch P, Veelken H,. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011; 117: 3836-3846.
27. Libri V, Azevedo RI, Jackson SE, Di MD, Lachmann R, Fuhrmann S, Vukmanovic-Stejic M, Yong K, Battistini L, Kern F, et al. Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4+ CD45RA+ CD27 T cells: The potential involvement of interleukin-7 in this process. Immunology 2011; 132: 326-339.
28. Okada R, Kondo T, Matsuki F, Takata H, Takiguchi M,. Phenotypic classification of human CD4+ T cell subsets and their differentiation. Int Immunol 2008; 20: 1189-1199.
29. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A,. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
30. Appay V, van Lier RA, Sallusto F, Roederer M,. Phenotype and function of human T lymphocyte subsets: Consensus and issues. Cytometry A 2008; 73A: 975-983.
31. Curfs JH, Meis JF, Hoogkamp-Korstanje JA,. A primer on cytokines: Sources, receptors, effects, and inducers. Clin Microbiol Rev 1997; 10: 742-780.
32. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
33. Boyum A,. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968; 97: 77-89.
34. Gachard N, Salviat A, Boutet C, Arnoulet C, Durrieu F, Lenormand B, Lepretre S, Olschwang S, Jardin F, Lafage-Pochitaloff M, et al. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. Haematologica 2008; 93: 215-223.
35. Roederer M,. Compensation in flow cytometry. Curr Protoc Cytom 2002;Chapter 1:Unit.
36. Roederer M, Darzynkiewicz Z, Parks DR,. Guidelines for the presentation of flow cytometric data. Methods Cell Biol 2004; 75: 241-256.
37. Kater AP, van Oers MH, Kipps TJ,. Cellular immune therapy for chronic lymphocytic leukemia. Blood 2007 Oct 15; 110: 2811-2818.
38. Kay S, Herishanu Y, Pick M, Rogowski O, Baron S, Naparstek E, Polliack A, Deutsch VR,. Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome. Cytometry B Clin Cytom 2006; 70B: 218-226.
39. Efremov DG, Gobessi S, Longo PG,. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun Rev 2007; 7: 102-108.
40. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, Weiss A, Kipps TJ,. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005; 105: 2036-2041.
41. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG,. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007; 109: 2032-2039.
42. Herishanu Y, Polliack A,. Chronic lymphocytic leukemia: A review of some new aspects of the biology, factors influencing prognosis and therapeutic options. Transfus Apher Sci 2005; 32: 85-97.
43. Peller S, Kaufman S,. Decreased CD45RA T cells in B-cell chronic lymphatic leukemia patients: Correlation with disease stage. Blood 1991; 78: 1569-1573.
44. Sallusto F, Lanzavecchia A,. Heterogeneity of CD4+ memory T cells: Functional modules for tailored immunity. Eur J Immunol 2009; 39: 2076-2082.
45. Zhu J, Yamane H, Paul WE,. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010; 28: 445-489.
46. McKinstry KK, Strutt TM, Swain SL,. The potential of CD4 T-cell memory. Immunology 2010; 130: 1-9.
47. Dooms H, Abbas AK,. Control of CD4+ T-cell memory by cytokines and costimulators. Immunol Rev 2006; 211: 23-38.
48. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von Bergwelt-Baildon M, Debey S, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018-2025.
49. Biancotto A, Dagur PK, Fuchs JC, Wiestner A, Bagwell CB, McCoy JP Jr,. Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia. Mod Pathol 2012; 25: 246-259.
50. Giannopoulos K, Schmitt M, Wlasiuk P, Chen J, Bojarska-Junak A, Kowal M, Rolinski J, Dmoszynska A,. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008; 22: 222-224.
51. Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, Rolinski J, Dmoszynska A,. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008; 20: 677-682.
52. Weiss EM, Schmidt A, Vobis D, Garbi N, Lahl K, Mayer CT, Sparwasser T, Ludwig A, Suri-Payer E, Oberle N, et al. Foxp3-mediated suppression of CD95L expression confers resistance to activation-induced cell death in regulatory T cells. J Immunol 2011; 187: 1684-1691.
53. Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC,. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol 2013; 4: 129.
54. Lagneaux L, Delforge A, Bron D, Bosmans E, Stryckmans P,. Comparative analysis of cytokines released by bone marrow stromal cells from normal donors and B-cell chronic lymphocytic leukemic patients. Leuk Lymphoma 1995; 17: 127-133.
55. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256-263.
56. Kay NE, Han L, Bone N, Williams G,. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: Impact on clonal B-cell apoptosis. Br J Haematol 2001; 112: 760-767.